

Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)

Technology appraisal guidance

Published: 1 October 2025

www.nice.org.uk/guidance/ta1100

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 years. This is because Astellas Pharma has confirmed that it does not intend to make a submission for the appraisal. Astellas Pharma considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this population.

Information

If NHS organisations wish to consider mirabegron for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7219-7